


# CA-ADAP Utilization: DULAGLUTIDE (TRULICITY)

JANUARY 17, 2024


CARRIE HOLDEN, PHARM.D

**MagellanRx**  
MANAGEMENT<sup>SM</sup>


# % OF TOTAL FILLS BY MONTH



# % of Clients with Diabetes Med Claims



% of Clients with DM Claims



# Confidentiality statement



*By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.*

*The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.*

*The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.*